Next-generation disulfide stapling: reduction and functional re-bridging all in one by Lee, MTW et al.
Chemical
Science
EDGE ARTICLE
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
5 
Se
pt
em
be
r 2
01
5.
 D
ow
nl
oa
de
d 
on
 2
4/
07
/2
01
7 
15
:5
8:
17
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
View Journal  | View IssueNext-generationDepartment of Chemistry, University Colle
WC1H 0AJ, United Kingdom. E-mail: v.chud
† Electronic supplementary information (
for all small molecules, LC-MS, SDS-PA
applicable) for all bioconjugates. See DOI
Cite this: Chem. Sci., 2016, 7, 799
Received 22nd July 2015
Accepted 13th September 2015
DOI: 10.1039/c5sc02666k
www.rsc.org/chemicalscience
This journal is © The Royal Society of Cdisulﬁde stapling: reduction and
functional re-bridging all in one†
Maximillian T. W. Lee, Antoine Maruani, James R. Baker, Stephen Caddick
and Vijay Chudasama*
Herein we present a signiﬁcant step towards next-generation disulﬁde stapling reagents. A novel class of
reagent has been designed to eﬀect both disulﬁde reduction and functional re-bridging. The strategy has
been applied to great success across various peptides and proteins. Moreover, application to a multi-
disulﬁde system resulted in functional re-bridging without disulﬁde scrambling.Advances in protein modication by chemical means have led
to the development of a range of protein bioconjugation
methodologies.1 These methodologies have been successfully
applied to a number of elds such as the uorescent tagging of
proteins,2 the development of therapeutic protein conjugates3,4
to treat indications such as HIV,5 cancer6 and malaria,7 and for
use as diagnostic tools.8
Whilst a large number of reagents and protocols have been
developed to modify proteins, novel strategies for site-specic
conjugation continue to attract considerable interest in view of
the increasingly stringent requirements in the development of
biologics.1 Several amino acid side-chains have been targeted
for site-selective modication over the past few decades, e.g.
tryptophan, histidine, tyrosine and, in particular, lysine and
cysteine. However, the modication of native disuldes through
functional re-bridging, pioneered by Brocchini et al., has
attracted signicant interest in recent years with various
approaches being developed.9–13
Recently, Chudasama, Caddick et al. have shown dibromo-
pyridazinediones to be viable candidates for disulde stapling
and that the resulting bisthioether is stable in blood plasma-
mimicking conditions.9j Whilst this approach, as well as others,
oﬀer advances in this growing eld of disulde labelling, a
common limitation is the requirement for reduction and re-
bridging in distinct steps. This is mainly due to the incompat-
ibility of the bridging and reducing agents. This introduces
ineﬃciencies in terms of cost, time and practicality. Whilst one-
pot in situ methods have been employed, this is only at the
expense of using a vast excess of reducing and bridging agents
to compensate for the reaction between the two reagents.9jge London, 20 Gordon Street, London,
asama@ucl.ac.uk; Tel: +44207 679 2077
ESI) available: 1H and 13C NMR spectra
GE gels and UV-Vis analysis (where
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hemistry 2016In view of the above, we set about designing a reagent that
could incorporate both reducing and re-bridging functions
(Fig. 1). During the course of our previous studies, we observed
dithiophenolpyridazinediones to be unreactive towards
commonly used disulde reducing agent tris(2-carboxyethyl)
phosphine (TCEP). In light of this, TCEP moieties were a logical
choice for incorporation into a dithiophenolpyridazinedione.
More specically, the TCEP functional moieties were to be
tethered onto the thiophenol groups of the dithiophenolpyr-
idazinedione since these groups would be extruded post-bio-
conjugation with a reduced disulde.
A suitable route to a dithioaryl(TCEP)pyridazinedione was
conceived (Scheme 1). Initially, TFA cleavage of the Boc groups
of di-Boc-diethylhydrazine 1, followed by reaction with dibro-
momaleic anhydride under reux in AcOH, aﬀorded diethyl
dibromopyridazinedione 2. This dibromopyridazinedione was
reacted with 4-aminothiophenol to form dithioarylpyr-
idazinedione 3, which was nally coupled to mono-acid TCEP
derivative 4 to form target dithioaryl(TCEP)pyridazinedione 5.
With dithioaryl(TCEP)pyridazinedione 5 in hand, we
appraised its suitability as a bioconjugation reagent for both
disulde reduction and functional re-bridging. To do this,Fig. 1 Illustration highlighting previous strategies towards disulﬁde
stapling and the novel strategy described in this manuscript.
Chem. Sci., 2016, 7, 799–802 | 799
Scheme 1 Synthesis of dithioaryl(TCEP)pyridazinedione 5. Reagents
and conditions: (i) TFA, CH2Cl2, 21 C, 1 h; (ii) dibromomaleic anhy-
dride, AcOH, reﬂux, 2 h; (iii) 4-aminothiophenol, NEt3, CH2Cl2, 21 C,
2 h; (iv) acid 4, DMF, HATU, DIPEA, 21 C, 12 h.
Scheme 3 Pre-incubation of Fab fragment of Herceptin™ with pyr-
idazinedione 6, followed by addition of 5 aﬀords product derived from
reagent 5 only.
Chemical Science Edge Article
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View Article Onlinepyridazinedione 5 was incubated with a selection of biologically
relevant disulde containing peptides and proteins, i.e.
somatostatin, octreotide and a Fab (fragment antigen-binding)
arm of Herceptin™. To our delight, in each and every case,
pyridazinedione 5 was shown to reduce and functionally re-
bridge the singly accessible disulde (see Scheme 2 and ESI for
further details†). Moreover, only a small excess of “2-in-1”
reagent 5, 1.25 equivalents, was required to eﬀect complete
conversion. Another favourable property of pyridazinedione 5 is
that it is a solid which can be stored with complete stability over
a protracted period at 18 C under argon.
At this stage we rationalised that a molecule with both
reducing and re-bridging functions would minimise the resi-
dency time of the cysteines liberated from disulde reduction.
This is especially in view of no reduced protein being observed
upon incubation of the above peptides and proteins with
reagent 5 (see ESI for details†). To appraise this further, we
incubated the Fab fragment of Herceptin™ with 1, 2 and 5
equivalents of dipropyl-pyridazinedione 6 prior to incubation
with 2 equivalents of diethylpyridazinedione 5 (Scheme 3).
Validating our hypothesis, re-bridging was only observed with
the TCEP-bearing diethylpyridazinedione. The control reaction
of reducing the Fab prior to adding a mixture ofScheme 2 Functionally re-bridged somatostatin, octreotide and a Fab
of Herceptin™ using dithioaryl(TCEP)pyridazinedione 5.
800 | Chem. Sci., 2016, 7, 799–802pyridazinedione 5 and 6 aﬀorded a mixture of bioconjugates
(see ESI for details†).
With the knowledge of the use of dithioaryl(TCEP)pyr-
idazinedione 5 resulting in a high local concentration of the
specic pyridazinedione incorporated into the “2-in-1” scaﬀold,
we appraised the use of the reagent in the context of a multi-
disulde system. To do this, we chose to use Herceptin™ – an
antibody comprising four disulde bonds – whose disulde
bonds can be scrambled on attempted functional disulde re-
bridging.9h Although this scrambling can be minimised, the
leading strategy is reagent specic.9j We rationalised that the
use of pyridazinedione 5 would ensure minimisation ofFig. 2 Appraisal of the use of pyridazinediones 3 (in situ 4 C (pre-
reduced, portion-wise reduction), 37 C) and 5 for functional re-
bridging of Herceptin™.
This journal is © The Royal Society of Chemistry 2016
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View Article Onlinedisulde scrambling in a general sense. To this end, pyr-
idazinediones 3 (with no internal reducing agent function) and
5 (with reducing agent function) were reacted with Herceptin™
under the appropriate reaction conditions, i.e. reaction with
pyridazinedione 3 required reduction of Herceptin™ with
TCEP. Gratifyingly, no disulde scrambling was observed by
SDS-PAGE for reagent 5, with complete re-bridging of all
disuldes conrmed by UV-Vis (Fig. 2, lane 4). Analogous
reagent 3, with no inherent reducing capability, aﬀorded a
disulde scrambled product (Fig. 2, lane 2). Even when dithio-
pyridazinedione 3 was used in excess and TCEP was added in
small portions multiple times (6 0.33 eq per disulde every 30
min), i.e. to minimise the number of open disuldes at any
given time, disulde scrambling was still observed (Fig. 2, lane
3). Although scrambling was far less pronounced, the reaction
protocol is highly cumbersome and ineﬃcient. Reaction of
dithiopyridazinedione 3 at 37 C also aﬀorded a mixture of
products (Fig. 2, lane 5). Furthermore, reaction of pyr-
idazinedione 2 at 4 C and 37 C also aﬀorded a mixture of
correctly and incorrectly re-bridged modied Herceptin™
conjugates (see ESI for details†).
Providing a reagent that can functionally re-bridge the
disulde bonds of Herceptin™ without disulde scrambling is
a major contribution in view of the desire to create homogenous
conjugates in the eld of antibody–drug conjugates.14 Use ofScheme 4 Application of alkyne bearing pyridazinedione 7 for disul-
ﬁde reduction and re-bridging as well as “click” functionalisation of the
product with various azides to form bioconjugates 9a–c.
This journal is © The Royal Society of Chemistry 2016Herceptin™, in view of its clinical validation alone and as the
antibody component of FDA-approved ADC Kadcyla™,15
provides direct applicability of the chemistry to this exciting
area of targeted therapy.
To make this approach modular and expand its scope, we
synthesised an analogue of pyridazinedione 5, which contained
an alkyne handle for “click” functionalisation, in alkyne-pyr-
idazinedione 7 (see Scheme 4). An analogous route to that
described in Scheme 1 was followed (see ESI for further
details†). The appraisal of this molecule was carried on the Fab
fragment of Herceptin™ as this would allow extensive analysis
by UV-Vis, MS, SDS-PAGE and ELISA (for binding). The opti-
mised conditions for the insertion of dithioaryl(TCEP)pyr-
idazinedione 5, was applied to the alkyne bearing analogue for
the functional re-bridging of the Fab fragment of Herceptin™
to form conjugate 8. The eﬃciency of reduction and re-bridging
was translated cleanly from reagent 5 to alkyne analogue 7 by
MS, SDS-PAGE and UV-Vis (see Scheme 4 and ESI for further
details†).
Finally, conjugate 8 was functionalised by “click” modica-
tion using doxorubicin, AlexaFluor488™ and sulfo-cyanine5
azides (see Scheme 4). In all cases, complete conversion was
observed to aﬀord functionalised conjugates 9a–c, thus
demonstrating how the platform may be used for eﬃcient
introduction of functional modalities as well as reduction and
re-bridging. Moreover, the binding of the Fab protein was not
compromised, by ELISA analysis (see ESI for details†), through
the chemistry applied. Pyridazinedione 7 was also shown to
successfully re-bridge the full antibody system of Herceptin™
and be amenable to “click” functionalisation with doxorubicin
azide (see ESI for details†).Conclusions
In conclusion, we have provided an important step towards
delivering on next-generation disulde stapling. This rst-in
class technology allows for reduction and functional re-bridging
by the use of a single reagent. Moreover, this strategy has been
shown to result in a high local concentration of bridging agent,
which has been exploited for the functional re-bridging of a
multi-disulde system (i.e. Herceptin™) without disulde
scrambling. Finally, facile “click” functionalisation and reten-
tion of binding aﬃnity, using our strategy, has been demon-
strated on a Fab of Herceptin™.Acknowledgements
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